Merck Serono partners with Ono to treat cancer and MS

10/4/2011 | Genetic Engineering & Biotechnology News

Ono Pharmaceuticals and Merck Serono entered two agreements covering the former's ONO-4641, a midstage oral compound for multiple sclerosis, and the latter's Stimuvax, a late-stage immunotherapy for cancer. The first deal gives Merck Serono worldwide rights excluding Taiwan, South Korea and Japan to ONO-4641 for $18.75 million upfront plus milestone fees. For the second contract, Ono will pay Merck Serono about $6.7 million upfront for Japanese co-development and co-commercialization rights to Stimuvax.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA